NCT05243641View on ClinicalTrials.gov

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 18, 2022

Primary Completion Date

November 19, 2024

Study Completion Date

November 19, 2024

Conditions
Metastatic Breast CancerBreast Cancer
Interventions
DRUG

Neratinib

Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.

DRUG

Capmatinib

Capmatinib will be supplied at 200 mg and 150 mg tablets

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (2)

Celcuity Inc
Novartis
All Listed Sponsors
collaborator

Celcuity Inc

INDUSTRY

collaborator

Novartis

INDUSTRY

collaborator

Puma Biotechnology, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER